Best practices for endoscopic surveillance of Barrett’s esophagus

Barrett’s esophagus develops when chronic gastroesophageal reflux causes the normal lining of the lower esophagus to change. Although the condition can remain stable for years, it increases the risk of esophageal adenocarcinoma. Structured endoscopic monitoring helps identify dysplasia or early cancer when treatment is most effective.

Surveillance is more than repeating an upper endoscopy at fixed intervals. Reliable care depends on confirming the diagnosis, documenting the extent of intestinal metaplasia, using high-definition imaging, obtaining targeted biopsies, and ensuring that pathology is reviewed by an experienced gastrointestinal pathologist.

The educational sessions and research discussions associated with the International Society for Diseases of the Esophagus emphasize the value of consistent standards across specialists. These principles remain useful for clinicians developing local pathways for Barrett’s esophagus monitoring.

Confirm the diagnosis and document risk

The initial examination should establish whether specialized intestinal metaplasia is present in the tubular esophagus. The endoscopist should describe the gastroesophageal junction, diaphragmatic hiatus, and the visible extent of Barrett’s mucosa using a recognized system such as the Prague C and M classification.

A complete report records the circumferential and maximal length, visible nodules, ulcers, strictures, erosions, and any other suspicious lesions. Photographic documentation supports future comparisons. Gastric cardia intestinal metaplasia should not automatically be classified as Barrett’s esophagus.

Risk assessment also includes age, sex, family history of esophageal adenocarcinoma, smoking, obesity, reflux burden, and segment length. These factors help clinicians individualize counseling, although surveillance intervals should follow evidence-based regional guidelines rather than informal risk estimates.

Prepare the patient and optimize visualization

Patients generally require careful reflux management and appropriate fasting before the procedure. Inadequate preparation, retained food, active bleeding, or severe inflammation can obscure subtle abnormalities and may justify repeat assessment after healing.

High-definition white-light endoscopy should be combined with image-enhanced techniques, such as virtual chromoendoscopy or acetic acid where appropriate. The examination should proceed methodically, inspecting all Barrett’s mucosa and the surrounding squamocolumnar junction.

Any visible lesion deserves focused evaluation before random sampling. The report should describe its location, size, surface pattern, borders, and morphology, and should state whether it was biopsied or removed. Targeted resection is often preferable to simply sampling a suspicious area.

Use a systematic biopsy protocol

For flat, apparently nondysplastic mucosa, four-quadrant biopsies taken at regular intervals remain a practical surveillance method. Shorter segments may require biopsies from each visible area rather than rigid spacing. Separate specimen containers by anatomical level improve pathological interpretation.

Visible abnormalities should be sampled separately or removed by endoscopic mucosal resection when technically appropriate. Mixing tissue from a nodule with random surveillance samples can conceal clinically important findings and make treatment planning harder.

Pathology should distinguish no dysplasia, indefinite for dysplasia, low-grade dysplasia, high-grade dysplasia, and invasive carcinoma. Dysplasia diagnoses, especially low-grade changes, should be confirmed by a second expert gastrointestinal pathologist because inflammation and tangential sectioning can produce false-positive interpretations.

Match surveillance intervals to findings

Intervals depend on the presence of dysplasia, the length of the Barrett’s segment, the quality of the examination, and the guideline used in the patient’s region. A high-quality baseline examination is essential before assigning a long interval.

Patients with confirmed dysplasia should generally be managed in an expert center or multidisciplinary setting. Endoscopic eradication therapy is commonly favored for high-grade dysplasia and early intramucosal cancer, while selected patients with confirmed low-grade dysplasia may undergo eradication therapy or carefully structured surveillance.

These timeframes are illustrative rather than universal. Published recommendations differ, and clinicians should apply current local guidance, patient comorbidities, and the findings of the most recent examination.

Manage dysplasia with an expert team

Endoscopic resection is important when a lesion is visible because it provides accurate staging and can remove focal disease. Ablation, frequently using radiofrequency techniques, may be considered for residual flat dysplastic Barrett’s mucosa after resection of visible abnormalities.

After eradication therapy, patients need structured follow-up because recurrent or residual intestinal metaplasia can occur. Surveillance should continue according to the original degree of dysplasia and the patient’s treatment response, even when the esophagus appears normal.

Acid suppression is usually maintained during surveillance and after eradication therapy to control reflux and support mucosal healing. Lifestyle measures, including weight management and smoking cessation, can complement medical treatment but do not replace endoscopic monitoring.

Build a dependable surveillance pathway

Quality assurance should track examination completeness, use of standardized terminology, biopsy adherence, detection of visible lesions, pathology concordance, and follow-up attendance. Endoscopists who perform surveillance regularly can improve consistency through audit, peer review, and continuing education.

Practical steps that strengthen care include:

• Record Prague classification and landmarks in every relevant report.
• Use high-definition imaging and carefully inspect for subtle lesions.
• Separate biopsy specimens by level and identify visible abnormalities clearly.
• Obtain expert review for any diagnosis of dysplasia.
• Refer complex disease and eradication therapy to experienced centers.

Patients should understand why surveillance is recommended, what symptoms require prompt review, and why keeping scheduled examinations matters even when reflux symptoms are controlled. Shared decisions are particularly important for older adults or people with significant comorbidity, where the potential benefit of repeated procedures may change over time.

Reliable Barrett’s esophagus surveillance combines careful endoscopy, disciplined sampling, expert pathology, and appropriate escalation when dysplasia appears. Review current society guidance and incorporate these principles into local protocols, education programs, and multidisciplinary practice through the ongoing resources of the International Society for Diseases of the Esophagus.